Risk estimation for recurrent clostridium difficile infection based on clinical factors

Clinical Infectious Diseases

Volumn 58, Issue 10, 2014, Pages 1386-1393

  D'Agostino Sr, Ralph B ^a   Collins, Sylva H ^b   Pencina, Karol M ^a   Kean, Yin ^c   Gorbach, Sherwood ^b  

^a BOSTON UNIVERSITY   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c Independent Consultant   (United States)

Author keywords

CDI; Clostridium difficile infection; Fidaxomicin; Vancomycin

Indexed keywords

CREATININE; FIDAXOMICIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CREATINE;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RISK FACTOR; VITAL SIGN; AGE; BLOOD; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; CONTROLLED STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CREATINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; RECURRENCE; RISK FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 84899796356     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu107     Document Type: Article

References (34)

1. Gerding DN. Clostridium difficile infection prevention: biotherapeutics,immunologics, and vaccines. Discov Med 2012; 13:75-83.
2. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI)in hospital stays, 2009. HCUP statistical brief no. 124. Rockville, MD:US Department of Health and Human Services, Agency for HealthcareResearch and Quality, 2011. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/ sb124.pdf.
3. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, FalagasME. Treatment failure and recurrence of Clostridium difficile infectionfollowing treatment with vancomycin or metronidazole: a systematic reviewof the evidence. Int J Antimicrob Agents 2012; 40:1-8.
4. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavorableoutcomes in Clostridium difficile infection: a systematic review. PLoSOne 2012; 7:E30258.
5. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycinfor infection with Clostridium difficile in Europe, Canada, andthe USA: a double-blind non-inferiority, randomized controlled trials.Lancet Infect Dis 2012; 12:281-9.
6. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycinfor Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
7. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. Wileyseries in probability and statistics. New York: Wiley, 2000.
8. Zhou XH, McClish DK, Obuchowski NA. Statistical methods in diagnosticmedicine. New York: Wiley, 2003.
9. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Commentson integrated discrimination and net reclassification improvements-practical advice. Stat Med 2008; 27:207-12.
10. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluatingthe added predictive ability of a new marker: from area under the ROCcurve to reclassification and beyond. Stat Med 2008; 27:157-72.
11. Pencina MJ, D'Agostino RB Sr, Demler OV. Novel metrics for evaluatingimprovement in discrimination: net reclassification and integrateddiscrimination improvement for normal variables and nested models.Stat Med 2012; 31:101-13.
12. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariatedata for clinical use: the Framingham Study risk score functions.Stat Med 2004; 23:1631-6.
13. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascularrisk profile for use in primary care. Circulation 2008; 117:743-53.
14. Bartlett JG. The case for vancomycin as the preferred drug fortreatment of Clostridium difficile infection. Clin Infect Dis 2008;46:1489-92.
15. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycinand metronidazole for the treatment of Clostridium difficileassociateddiarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
16. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcaresystem. Clin Infect Dis 2012; 55(suppl 2):S88-92.
17. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economichealthcare costs of Clostridium difficile infection: a systematic review.J Hosp Infect 2010; 74:309-18.
18. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrheaand colitis. World J Gastroenterol 2009; 15:1554-80.
19. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridiumdifficile infection. J Infect 2010; 61:1-8.
20. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection:new developments in epidemiology and pathogenesis. Nat Rev Microbiol2009; 7:526-36.
21. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC.Epidemiology of recurrences or reinfections of Clostridium difficileassociateddiarrhea. J Clin Microbiol 2000; 38:2386-8.
22. Wilcox MH. Treatment of Clostridium difficile infection. J AntimicrobChemother 1998;41(suppl C):41-6.
23. Figueroa I, Johnson S, Sambol SP, Goldstein EJC, Citron DM, GerdingDN. Relapse versus reinfection: recurrent Clostridium difficile infectionfollowing treatment with fidaxomicin or vancomycin. Clin Infect Dis2012; 55(suppl 2):S104-9.
24. Noren T, Akerlund T, Back E, et al. Molecular epidemiology of hospitalassociatedand community-acquired Clostridium difficile infection in aSwedish county. J Clin Microbiol 2004; 42:3635-43.
25. Tang-Feldman Y, Mayo S, Silva J Jr, Cohen SH. Molecular analysis ofClostridium difficile strains isolated from 18 cases of recurrent Clostridiumdifficile-associated diarrhea. J Clin Microbiol 2003; 41:3413-4.
26. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect of vancomycinon intestinal flora of patients who previously received antimicrobialtherapy. Clin Infect Dis 1997; 25:729-32.
27. Fekety R. Guidelines for the diagnosis and management of Clostridiumdifficile-associated diarrhea and colitis. American College of Gastroenterology,Practice Parameters Committee. Am J Gastroenterol 1997;92:739-50.
28. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinalmicrobiome during and after treatment of Clostridium difficile infection(CDI) and reduces both toxin reexpression and recurrence of CDI. ClinInfect Dis 2012; 55(suppl 2):S132-42.
29. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatmentstrategies for 163 cases of recurrent Clostridium difficile disease. Am JGastroenterol 2002; 97:1769-75.
30. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, GreenbergRN. Recurrent Clostridium difficile disease: epidemiology and clinicalcharacteristics. Infect Control Hosp Epidemiol 1999; 20:43-50.
31. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes ofa first recurrence of Clostridium difficile-associated disease in Quebec,Canada. Clin Infect Dis 2006; 42:758-64.
32. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibioticexposure on the human intestinal microbiota. Microbiology2010; 156(pt 11):3216-23.
33. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic,fidaxomicin (OPT-80), causes less alteration to the bowel microbiota ofClostridium difficile-infected patients than does vancomycin. Microbiology2010; 156(pt 11):3354-9.
34. Johnson S. Recurrent Clostridium difficile infection: causality and therapeuticapproaches. Int J Antimicrob Agents 2009; 33(suppl 1):S33-6.